Product Description
Debio 0432 is a small molecule with best-in-class potential that could be deployed to combat multiple tumor types. Through its potent and selective inhibition of USP1, a critical player in DNA damage repair (DDR) pathway, Debio 0432 has the potential to induce synthetic lethality in tumor types with underlying defects of DNA repair genes (such as BCRA1). 'Synthetic lethality, a process in which alterations in at least two different genes result in cell death due to inability of repairing DNA defects, is a novel and promising cancer therapy. (Sourced from: https://www.debiopharm.com/pipeline/debio-0432/)
Mechanisms of Action: USP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Debiopharm
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/04/2024 |
News Article |
Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego |
|
03/26/2024 |
News Article |
Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432 |
|
03/02/2023 |
News Article |
DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY |
|
03/02/2023 |
News Article |
DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY |